Among the 145 patients with HER2+ breast cancer, 118 (81.4%) received neoadjuvant chemotherapy plus trastuzumab, while 27 (18.6%) received neoadjuvant chemotherapy plus trastuzumab and pertuzumab (Table 1). This evidence concerns the gene ERBB2 and breast cancer.